ACADIA Pharmaceuticals Inc (ACAD)
17.07
-0.12
(-0.70%)
USD |
NASDAQ |
Apr 18, 16:00
17.08
0.00 (0.00%)
After-Hours: 20:00
ACADIA Pharmaceuticals Cash from Financing (Quarterly): 5.434M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.434M |
| September 30, 2023 | 12.75M |
| June 30, 2023 | 5.478M |
| March 31, 2023 | 1.466M |
| December 31, 2022 | 1.614M |
| September 30, 2022 | 0.287M |
| June 30, 2022 | 3.831M |
| March 31, 2022 | 2.467M |
| December 31, 2021 | 4.365M |
| September 30, 2021 | 1.066M |
| June 30, 2021 | 5.005M |
| March 31, 2021 | 7.726M |
| December 31, 2020 | 18.13M |
| September 30, 2020 | 11.72M |
| June 30, 2020 | 47.40M |
| March 31, 2020 | 3.754M |
| December 31, 2019 | 43.06M |
| September 30, 2019 | 319.97M |
| June 30, 2019 | 4.646M |
| March 31, 2019 | 4.176M |
| December 31, 2018 | 300.60M |
| September 30, 2018 | 0.211M |
| June 30, 2018 | 2.953M |
| March 31, 2018 | 2.88M |
| December 31, 2017 | 4.791M |
| Date | Value |
|---|---|
| September 30, 2017 | 7.897M |
| June 30, 2017 | 7.01M |
| March 31, 2017 | 11.49M |
| December 31, 2016 | 3.986M |
| September 30, 2016 | 226.08M |
| June 30, 2016 | 20.76M |
| March 31, 2016 | 282.99M |
| December 31, 2015 | 9.332M |
| September 30, 2015 | 1.132M |
| June 30, 2015 | 2.599M |
| March 31, 2015 | 1.439M |
| December 31, 2014 | 2.807M |
| September 30, 2014 | 1.282M |
| June 30, 2014 | 1.72M |
| March 31, 2014 | 198.04M |
| December 31, 2013 | 0.629M |
| September 30, 2013 | 0.974M |
| June 30, 2013 | 109.87M |
| March 31, 2013 | 0.208M |
| December 31, 2012 | 91.23M |
| September 30, 2012 | 6.86M |
| June 30, 2012 | 0.057M |
| March 31, 2012 | 0.022M |
| December 31, 2011 | 0.097M |
| September 30, 2011 | -0.01M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.287M
Minimum
Sep 2022
319.97M
Maximum
Sep 2019
26.32M
Average
5.005M
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| Tonix Pharmaceuticals Holding Corp | 40.71M |
| Amylyx Pharmaceuticals Inc | 0.23M |
| Regulus Therapeutics Inc | -0.873M |
| Minerva Neurosciences Inc | 0.00 |
| Viking Therapeutics Inc | 0.188M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 85.39M |
| Cash from Investing (Quarterly) | -0.347M |
| Free Cash Flow | -23.35M |
| Free Cash Flow Per Share (Quarterly) | 0.5181 |
| Free Cash Flow to Equity (Quarterly) | 85.39M |
| Free Cash Flow to Firm (Quarterly) | 85.39M |
| Free Cash Flow Yield | -0.83% |